Amsterdam UMC | IBD Center - Clinical Trial Unit
Status
Conditions
Treatments
About
Evaluate the efficacy and safety of the C2 CryoBalloon 180° Ablatie Systeem (CBAS180) at decremental doses for the treatment of dysplastic Barrett's epithelium.
Full description
Cryoballoon ablation is a relatively new ablation technique for the treatment of dysplastic Barrett's esophagus (BE). Previous studies with this technique have shown that treatment is safe and effective. When compared to other ablation techniques, cryoballon ablation has several potential advantages, including less pain and less complications such as stricture formation after treatment. Recently, a cryoballoon ablation system has become available which enables treatment of larger esophageal surfaces. Although a recent clinical study with this new device has shown promising results, the lowest possible dose that optimally balances safety and efficacy is still unknown.
This study is a multicenter, prospective, intervention study consisting of two phases: the treatment phase and the follow-up phase.
During the treatment phase, patients will undergo an upper endoscopy during which CBAS180 treatment will be performed. Treatment consists of two CBAS180 applications, starting just below the gastroesophageal junction (GEJ), resulting in a circumferential ablation of 3cm in length. During the treatment phase, two doses will be tested consecutively starting with the lowest dose (i.e. 1.2mm/sec). For each dose a total of 25 patients will be included. An interim analysis will be performed after treatment of the first 25 patients with the lowest dose of 1.2mm/sec, before proceeding to treatment of the additional 25 patients with a higher dose of 1.1mm/sec.
The follow-up phase starts after CBAS180 treatment and ends after first follow-up endoscopy at 10 weeks (±2 weeks) after treatment. Therefore, the study duration will be approximately 3 months for each individual patient. The investigators expect to report the primary outcome for all participating patients within 2 years.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Flat type BE esophagus, with an indication for ablation therapy, defined as:
Prague Classification Score of C≤3 and M≥1.
Patients should be ablation-naïve, meaning they have not undergone any previous endoscopic ablation therapy of the esophagus.
Older than 18 years of age at time of consent.
Fit for endoscopic therapy per institution's standards.
Provides written informed consent on the IRB-approved informed consent form.
Willing and able to comply with follow-up requirements.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
62 participants in 1 patient group
Loading...
Central trial contact
Koen Munters, Msc
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal